title: Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Miura
authors.forename: Takayuki
authors.initials: T
authors.lastname: Azuma
authors.forename: Eiji
authors.initials: E
authors.lastname: Kusumi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Matsumura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kami
authors.forename: Tsunehiko
authors.initials: T
authors.lastname: Komatsu
mesh_terms: D000368:Aged; D002066:Busulfan / Q000008:administration & dosage; D036101:Cord Blood Stem Cell Transplantation; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control; D020350:Graft vs Tumor Effect / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D019653:Myeloablative Agonists / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D016559:Tacrolimus / Q000008:administration & dosage; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine; D016559:Tacrolimus